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Abstract
Objective—We aimed to examine if smoking is an independent predictor of oral candidiasis
(OC) among HIV-1 infected persons.
Methods—The cross-sectional part of this study evaluated 631 adult dentate HIV-1 seropositive
persons examined for OC from 1995 – 2000 at the University of North Carolina Hospitals in
Chapel Hill, NC. In the second part, from the above sample, 283 individuals who were free of
HIV-associated oral diseases at baseline were followed up for two years to assess incident OC
events. Data collected from medical record review, interview questionnaires and clinical
examinations were analyzed using chi-square tests and t-tests. Logistic regression models were
developed for prevalent OC employing the likelihood ratio test, whereas Poisson regression
models were developed for assessing cumulative incidence of OC. These models included a
variety of independent variables to adjust for confounding.
Results—Thirteen percent of participants had OC only; 4.6% had OC with Oral Hairy
Leukoplakia; and 69.7% had neither. Smoking was associated with OC in all models [prevalent
OC - current smokers: logistic regression – Odd Ratio (95% CI) = 2.5 (1.3, 4.8); Incident OC -
current smokers: Poisson regression (main effects model) - Incidence Rate Ratio (95% CI) = 1.9
(1.1, 3.8)]. Other Poisson regression models suggested evidence for effect modification between
CD4 cell count and incident OC by smoking.
Conclusion—Smoking is an independent risk factor for development of OC in HIV-1 infected
persons and the risk of OC is modified by CD4 cell count which measures strength of the immune
system.
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INTRODUCTION
Oral candidiasis (OC) is the most frequent opportunistic fungal infection among human
immunodeficiency virus (HIV)-infected patients with incident rate/density of 9.3 per 1000
person months and a strong correlation with immune suppression as measured by reduced
CD4 cell counts (<200 cells/mm3) (1). Occurrence of OC in HIV-infected persons has been
reported globally and it continues to have a major public health impact despite studies
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demonstrating a declining incidence and prevalence since initiation of HAART, related
largely to improving immune status as measured by increasing CD4 counts (2–5). The
nature of HIV/AIDS has changed from an acute disease to a chronic disease after
introduction of HAART in developed countries. However, in countries where HIV/AIDS is
widespread and HAART medications are too expensive or patients are failing HAART, oral
disease management and risk remains an important issue. Resurgence of OC following
failure of HAART has been reported (6) with prevalence that is similar to the pre-HAART
era (7). Despite reports of reduced incidence of OC following HAART, it remains a
common opportunistic infection in HIV-infected patients (8–12).
The effect of smoking on OC in populations with HIV/AIDS remains controversial.
Whereas some studies have suggested association of smoking with OC (13–17), others
failed to find such an association (18), or found it only among patients with higher levels of
immune competence (CD4 counts ≥200 cells/mm3) (19). Most of these studies assess the
associations between OC and smoking in samples with prevalent OC. Only two studies have
reported incidence of OC (both in HIV-1 infected cohorts) – one in a cohort of HIV-positive
women (3) and the other in a mixed-gender sample (1). Both of these studies reported
greater risk of OC among current smokers after adjusting for several factors. Asymptomatic
oral Candida carriage has also been associated with smoking (20).
In conducting this study, our aim was to assess smoking as an independent risk factor for
OC among adults with HIV/AIDS and to examine for effect measure modification (EMM)
by smoking between OC and any other important risk factor, specifically the immune
marker, CD4 cell count. A CD4 cell count determines how well the immune system is
working, and it is well-established that a low CD4 count usually indicates a weakened
immune system and a higher chance of getting opportunistic infections.
METHODS
We evaluated a cohort of 631 HIV-positive persons at baseline in a longitudinal study with
yearly visits to establish independent risk factors/indicators for HIV- associated oral diseases
between 1995–2000 at the University of North Carolina (UNC) Hospitals in Chapel Hill,
North Carolina in this study approved by the UNC School of Medicine and UNC Hospitals
Committee on the Protection of the Rights of Human Subjects and NIH Institutional Review
Board. Comprehensive collection of medical and oral disease history and oral clinical
examinations was conducted. Assessment of oral manifestations of HIV was based on the
published standard presumptive clinical criteria (21) and conducted by a single Oral
Medicine trained examiner (LP). A medical record review was then conducted for each
participant to ascertain laboratory and medication variables and AIDS case status.
Univariate distributions of variables were assessed, as were bivariate relationships between
the covariates. Outcome variable was occurrence of OC. CD4 cell count was our main
explanatory variable (continuous variable as well as dichotomized as: < 200 vs. ≥200 cells/
mm3; and trichotomized as <200 vs. 200–500 cells mm3 vs. >500 cells mm3 depending on
the type of analysis) whereas other explanatory variables included age, sex, education level,
smoking history, drug use, sexual orientation, antiretroviral medication use and antifungal
medication use. Bivariate associations were assessed using t-tests, ANOVA; correlation
coefficients and chi-square tests as needed.
Multivariable analyses
We assessed the association between outcome and independent variables using bivariate
logistic regression, proportional odds models and Poisson regression analyses. Binary
unconditional logistic regression is used for two-level dependent variables (OC present/not
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present). The logistic regression analysis was conducted on the sample with complete
information for all variables for the prevalence study (n=623). Poisson regression analyses
were used to assess incident rate ratios (IRR) for incident OC using only those participants
that did not have any HIV-associated oral disease at baseline (n=283). Regression
diagnostics were performed, and the utility of the models was evaluated by outputting
predicted scores and residuals.
Analytical use of smoking variable: To conserve power in the incidence OC study, we
assessed smoking as a two-level variable (current smokers vs. current non-smokers). For the
prevalent OC study, we first analyzed smoking as a three-level variable (current, former,
never) to develop the binary logistic regression model and assess the role of smoking as an
independent predictor of OC. We then repeated these logistic regression analyses using
smoking as a two-level variable (current smokers vs. current non-smokers) to ascertain if the
relationship between smoking and OC was similar in both sets of analyses. By using the
same definition of smoking as an exposure variable in both analyses (Poisson regression and
logistic regression), we could then make appropriate comparisons between the models to
make inferences about the role of smoking as an independent predictor of OC.
The overall goal of each of the multivariable analyses was to control for potential
confounders, and to find the best fitting, most parsimonious and biologically reasonable
model to describe the relationship between OC and a set of independent explanatory
variables in which CD4 cell count was always included. All final main-effect models were
adjusted for: current CD4 cell count and antiretroviral medication. We arrived at the final
main-effects model to obtain the most useful model from a hierarchical series of models
after starting from a full model that was adjusted for: age, sex, race/ethnicity, education
level, sexual orientation, recreational drug use, baseline CD4 cell count, and antifungal
medication. To select between the hierarchically well-formulated models, we used the
likelihood ratio test carrying out all statistical analyses in SAS® (v9.1 Cary, NC, USA).
Upon developing the final main-effects models, we tested for statistical interaction between
smoking and CD4 cell count. The principal of a hierarchically well-formulated model
implies that for any given variable in the model, all lower-order components of the variables
must also be contained in the model. We inferred statistical significance using two sided p-
values at 0.05 level (a-priori: 0.1 for interaction terms) (22).
Where present, interactions were assessed through the interaction contrast (IC) defined as
the relative excess risk for interaction. Employing low CD4 cell count (<200 cells/mm3) and
current smoking as the two exposure variables, we calculated IC = R11 − R01 − R10 + R00;
where R01 and R10 are the risk estimates for exposure to any one of the exposures, R11 is
the risk estimate for doubly exposed, and R00 is the unitary value for the referent (doubly
unexposed) group (22).
RESULTS
Figure 1 shows the predicted incidence rates for OC among current smokers and
nonsmokers by CD4 cell count (cells/mm3) as a continuous variable demonstrating
declining rates with increasing CD4 cell count among both smokers and non-smokers
though the difference between smokers and non-smokers does not disappear completely.
Figure 2 shows the incidence rates for OC by CD4 cell count groups and smoking status.
Table 1 shows the results from main-effects models for logistic regression and Poisson
regression analysis after adjusting for a series of covariates mentioned in the methods
section. Assessment of smoking as a three level variable suggests current smokers had a
250% increase in risk for prevalent OC compared to those who had never smoked [OR (95%
CI): 2.5 (1.3, 4.8)]. Although the risk among former smokers was slightly elevated, it was
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not statistically significantly different from those who had never smoked. Furthermore,
similar levels of elevated risk among current smokers was maintained when they were
compared to never smokers and former smokers combined [OR: 2.3 (1.4, 3.7)]. Similarly,
current smokers had almost a 190% greater risk for developing new OC compared to current
non-smokers [IRR: 1.9 (1.1, 3.8)] in the main-effects model. These results suggest that
smoking is an independent risk factor for OC.
Upon further testing, we found evidence for statistical interaction between CD4 cell count
and smoking status in the final Poisson regression model mentioned above [variable (type-3
p-value pr>Chi-sq): CD4 cell count (0.0002), antiretroviral medication (0.0066); current
smoker (0.0244); CD4 * current smoker (0.0339)]. Therefore, the emphasis of assessing
smoking as a risk factor should address not the main-effects IRR presented above, but on the
within group IRRs calculated from the interaction model. Table 2 shows calculated IRRs
from the Poisson regression interaction models showing the modification of the association
between CD4 and OC by smoking, suggesting greater risk of OC among current smokers. IC
was calculated as: IC (R11 − R01 − R10 − R00) = 4.76 − 2.51 − 1.89 + 1.00 = 1.36 implying
positive departure from additivity or transadditivity (i.e. super additivity) of EMM in the
multiplicative scale (22).
DISCUSSION
In this longitudinal HIV-infected patient cohort study, we have demonstrated that smoking is
an independent risk factor for OC. However, the relationship between OC, immune
suppression (CD4 count) and smoking is not straight forward, but rather the risk for OC
varies across different CD4 count levels dependent upon current smoking status. Our
confidence in inferring causal association between smoking and OC, and suggesting
potential biological interaction between CD4 cell count and smoking status stems from the
finding of significant EMM in the incident disease study from assessing IRs in the Poisson
regression models, and biological plausibility in various studies (15).
Smoking has short and long-term effects on many important aspects of the inflammatory and
immune responses in the oral cavity (23). Tobacco smoke affects both cell-mediated and
humoral immunity (24, 25). Smoking impedes neutrophil transmigration across the oral and
periodontal microvasculature, suppresses neutrophil cell spreading, chemokinesis,
chemotaxis, and phagocytosis, and results in protease release from neutrophils that may be
an important mechanism in tissue destruction. In a normal oral mucosa fibroblast in vitro
model, fibroblasts exposed once to whole cigarette smoke, produced significant
morphological and functional deregulation and resulted in a significant inhibition of cell
adhesion, a decrease in the number of β1-integrin-positive cells, increased lactate
dehydrogenase activity in the target cells, and reduced growth which may explain the higher
predisposition of tobacco users to oral infections (26).
Tobacco smoking enhances oral candida colonization due to induction of increased
epithelial keratinisation (27), reductions in salivary immunoglobulin A levels (28), and
depression of polymorphonuclear leukocyte function (29). The association of smoking with
increased risk of clinical infection, or candidiasis, relates to an increased fungal burden,
reduced numbers of Langerhans cells and likely reduction of immunoglobulins (15). Both
bacterial and fungal populations are altered with tobacco exposure. Exposure to direct and
passive tobacco smoking has significant impact on a variety of gingival and oropharyngeal
flora (30). The flora of smokers contains fewer aerobic and anaerobic organisms with
interfering activity against bacterial pathogens and harbors more potential pathogens as
compared with the flora of non-smokers. Tobacco smoke compromises the antibacterial
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function of leukocytes, including neutrophils, monocytes, T-cells, and B-cells, providing a
mechanistic explanation for increased infection risk (23).
The in vitro effect of cigarette smoke condensate on ten clinical isolates of C. albicans
obtained from nonsmoking volunteers, as well as a culture collection strain, showed a
temporal increase in the secretion rates of enzymes, particularly when yeast cells were
exposed to cigarette smoke condensate for 48–72 h (31). Similarly, among denture wearers,
adhesion to acrylic and cell surface hydrophobicity increased with exposure period to
cigarette smoke condensate, leading authors to conclude that cigarette smoke may promote
significant enhancement in the secretion of candidal histolytic enzymes and adherence to
denture surfaces, thereby promoting oral yeast carriage and possible infection. The more
heavily an individual smokes, the more likely there will be Candida in the oral cavity (32).
Clinically, heavy smokers (smoked more than a pack a day) were shown to have a
significant 6 fold increased odds of candidiasis in patients with multiple oral leukoplakias
compared to lighter smokers (33), implying some level of dose-response effect may be
present.
Among patients with HIV infection, the severity and chronicity of OC has been largely
attributed to the HIV-associated immune deficiency (as expressed by reduced CD4 counts),
but may also relate to the virulence factors of the candidal pathogen. Adherence of the
fungus to oral mucosal tissues is the first step in colonization and disease initiation, with
extracellular hydrolases (proteinases and phospholipases) being major facilitators of tissue
invasion. After colonization and adhesion of Candida to the epithelial surface, potent
proteolytic enzymes or toxins and an inflammatory response to Candida antigens destroy
tissue that results in the subsequent mucosal lesion (34).
The relationship of Candida virulence to both smoking and HIV infection are not fully
understood. While a recent study comparing oral swab candidal isolates by HIV infection
status demonstrated isolates from HIV-positive patients were predominantly genotype A and
had significantly increased expression of proteinase, phospholipase and hemolytic activities,
as well as a greater ability to adhere, compared with HIV-negative individuals, no
significant differences in virulence factor expression in isolates colonizing or infecting HIV-
positive individuals were seen (35). Authors suggested HIV infection might lead to
preferential selection of C. albicans strains with altered virulence determinants that make
them more pathogenic; however, a relationship has not yet been established between the
genotypes and the virulence factors, or with clinical infection (35). In a study of patients
without HIV-infection, enhanced virulence was found in C. albicans from tongue and buccal
mucosa of chronic smokers, but oral candida loads did not differ between smokers and non-
smokers in that study population (36).
EMM may be assessed through statistical interaction in multivariable models. Examining
independent risk factors and interplay between them for occurrence of new cases of OC
offers an opportunity of addressing temporality to allow confident interpretation of
causality. Therefore, we examined EMM between CD4 cell counts and current smoking
towards incident OC. As seen in Table 2, for the two-variable interaction – outcome
association, the bivariate IRR corresponds to what would be “crude” IRR for one variable-
outcome association. Full model IRR shows the relationship when all covariates exist
whereas the final model IRR assesses the relationship in the most parsimonious model. In
each of the three situations, there is an incremental risk of incident OC when exposed to
smoking and/or low CD4 count. Therefore, among those with higher CD4 count, current
smokers exhibit greater risk of OC compared to nonsmokers. For example, in the final
model, compared to nonsmokers, smokers were 1.89 times as likely to get OC in the higher
CD4 groups.
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The general trend of increasing risk for OC with increasing exposure to smoking and low
CD4 cell count was exhibited in bivariate analyses, as well as the final model (Table 2). The
risk for OC was greatest among current smokers with low CD4 cell count compared to
current non-smokers with higher CD4 cell count, a group that can be viewed as not being
exposed to smoking or low CD4 cell count (i.e. doubly unexposed – R00). Compared to this
doubly unexposed group, exposure to either smoking or low CD4 cell count or both
increased the risk for OC. This finding demonstrates that although the magnitude of risk of
OC differs depending upon exposure types, risk of OC is higher among current smokers
thereby strengthening the argument that smoking is a strong independent risk factor for OC
development.
We noted a potential dose-response association as joint exposures to lower CD4 count and
current smoking was considered i.e. the risk for doubly exposed low CD4 cells/smoking
(final model IRR 4.76) was substantially greater than singly exposed (IRR 2.51 & 1.89)
which, in turn, was also substantially greater than the doubly unexposed (IRR 1.0 ~ referent
group). This trend was similar for bivariate as well as the fully adjusted models. In assessing
this change of risk across exposure categories, it is important to understand how much
increased risk each exposure offers. The column “incremental risk” in Table 2 addresses this
issue by ordering a sequence of increasing exposure and dividing the risk of outcome in
greater exposure categories (upper rows) by lesser exposure categories (lower rows). This
assessment suggested that compared to doubly unexposed, the exposure to smoking almost
doubled the risk of OC (incremental IRR – IIRR: 1.89). Compared to this group, in absence
of current smoking, exposure to lower CD4 cell count imparts another 33% increased risk
(IIRR: 1.33). However, compared to current nonsmokers with low CD4 cell count, the risk
of OC is nearly doubled by exposure to smoking (IIRR: 1.9). These results demonstrate that
for each CD4 cell count category, exposure to smoking nearly doubles the risk of OC.
Confounding can be estimated by assessing the departure of estimated adjusted risk from
their crude values after adjusting for confounders. The next question we addressed in these
analyses was the possibility of differential magnitude of confounding in different joint-
exposure strata. Although not generally discussed in the literature, it is assumed that each
strata of joint-exposures involved in EMM are confounded homogenously. Based on this
assumption, we would expect that the bivariate IRRs for each joint-exposure strata would be
equidistant from the IRRs of the adjusted model. The last column in Table 2 addresses this
issue. We assessed the percent change in risk estimates from their bivariate values (column
% change) by assessing the difference between the two estimates as a proportion of the
estimate of the final model.
The percent change column in Table 2 demonstrates that confounding by the common
factors in the model may impact different strata of joint-exposures differently in terms of
both direction and magnitude of confounding. For example, the percent change is positive
for higher CD4-smoker and low CD4-nonsmoker strata, but negative for the doubly exposed
group. Possible explanation of heterogeneity of confounding across factors involved in
EMM may include different thresholds or sets of biological mechanisms at play under
different exposure status and co-action of other factors or a role for unmeasured
confounding factors.
EMM between smoking and CD4 cell count in determining OC demonstrated in our analysis
suggests a type 2 response type (22), i.e. this association can be described as causal
association for OC with single plus joint coactions by low CD4 cell count and smoking
because compared to the doubly unexposed, the risk of OC was greater in those with low
CD4 cell groups as well as among those who smoked. Therefore, each factor may cause OC
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when the other is absent, i.e. they are not necessary conditions for OC (OC can occur in
other situations).
Under the sufficient cause model, low CD4 cell count can be classified as a necessary cause
for OC in this study because OC occurred among nonsmokers. This relationship between
CD4 cell count and smoking in determining OC can be classified as sufficient cause type B
(22) where one factor is necessary (low CD4 cell count) and the other is not (smoking).
However, risk of OC was greater even among higher CD4 cell count persons who smoked.
This apparent counter-intuitive outcome can be explained by the fact that to conserve power,
we defined the threshold of low CD4 cell count at 200 cells/mm3 where the OC risk is
highest. Immune compromise is still significant at CD4 cell counts higher than this threshold
which could explain the risk seen for higher CD4 cell count persons, many of whom would
be at greater risk due to CD4 cell count being not high enough to substantially reduce the
risk of OC (Figure 1). This fact is also expected to drive the incidence of OC among
nonsmokers. However, in the presence of low CD4 cell count as well as smoking exposure,
the risk for OC almost doubles as seen by the IRR figures in Table 2. These values suggest
coparticipation between low CD4 cell count and smoking to cause OC. This interaction is
also defined as causal coactions or synergism.
The effect of smoking on OC in populations with HIV/AIDS has been controversial. Our
analysis has been able to provide evidence that in HIV/AIDS, smoking is an independent
risk factor for OC in general and that this risk is greatest among those with low CD4 cell
count. Furthermore, we have been able to quantify these increased risks - on an average, the
risk for developing new OC is double among smokers compared to never-smokers/non-
smokers (Tables 1 & 2).
These results have direct clinical application. In general, health hazards due to smoking may
undermine benefits of HIV treatment on morbidity and mortality. Over 40 % of persons with
HIV are current smokers. (37) Considering the results of this study, it is clear that
incorporating smoking cessation advice and smoking-related education should be an
important component of clinical management of HIV/AIDS patients with OC as well as an
important component of OC prevention efforts.
CONCLUSION
We have been able to demonstrate that smoking is an independent risk factor for OC in
HIV-1 infected persons and this risk is modified by the CD4 cell count. The risk of OC
among those with low CD4 cell count who smoke is almost four and half times greater than
among those having high CD4 cell count and who do not smoke. This suggests that the
lower the CD4 cell count level, the more smoking enhances the individuals risk for OC.
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Predicted incidence rates for OC among current smokers and nonsmokers by CD4 cell count
(cells/mm3) at event: final models corresponding to each disease outcome, adjusted for
antiretroviral therapy, using CD4 cell count as a continuous variable.
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Observed incidence rates for OC among current smokers and nonsmokers by CD4 cell count
(categorized) at event: Smoker-Low CD4 cell count:1990.05; Smoker-High CD4 cell count:
2912.62; Non-smoker-Low CD4 cell count: 1116.07; and Non-smoker-Low CD4 cell count:
590.41 per 100,000 person-months.
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Table 1
Summary of risk factors/indicator associations with HIV associated oral diseases as seen in final multivariable
main-effects models (adjusted for age, sex, race/ethnicity, education level, sexual orientation, recreational
drug use, and antifungal medication (also baseline CD4 cell count in Poisson regression). Risk estimates are
presented as adjusted ORs (prevalent disease) and IRR (incident disease).
Prevalent OC Incident OC
Factor level Binary unconditional Logisticregression (n=623) Factor level
Binary unconditional
Logistic regression (n=623) Poisson regression (n=283)
Current smoker 2.5 (1.3, 4.8) Current smoker 2.3 (1.4, 3.7) 1.9 (1.1, 3.8)
Former smoker 1.2 (0.5, 2.7) Never/Former smoker 1 1
Never smoked 1
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Table 2
OC-Effect measure modification: CD4+ cell count and smoking: crude levels, bivariable and multivariable
Poisson regression models (IRR: incident rate ratio), testing from the model developed as shown in Table 1.
Grouping IRR: Bivariable IRR: Final model* Incremental IRR: Final model ** % Change(Fi – Bi)/Fi
Low CD4 - Smoker 5.16 4.76 1.9 -8.4
Low CD4 - non-Smoker 1.73 2.51 1.33 31.1
Higher CD4 – Smoker 1.56 1.89 1.89 17.5
Higher CD4 – non-Smoker 1 1 1 ---
*
Incremental IRR calculated as a ratio of stratum IRR with the IRR of the previous stratum in the table (i.e. 1.89/1 = 1.89; 2.51/1.89=1.33;
4.76/2.51=1.9).
**
IC = 4.76 − 2.51 − 1.89 + 1.00 = 1.36 implying positive departure from additivity or transadditivity (superadditivity) of effect measure
modification in the multiplicative scale. Low CD4 is <200 cells/mm3; High CD4 is ≥200 cells/mm3
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